Bruker, Agilent Reach Deal on Varian Product Lines Purchase

The sale of the product lines to Bruker will clear the way for Agilent to complete its $1.5 billion acquisition of Varian, which is now expected by the end of April.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.